Q-omics provides the consensus-scored HYOU1 profile across patient tissues and cancer cell-line models. HYOU1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HYOU1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HYOU1 protein abundance shows 20,755 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where HYOU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HYOU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HYOU1 survival associations across molecular data types. HYOU1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HYOU1 RNA expression–survival associations across cancer types. High HYOU1 expression shows unfavorable associations in BLCA, ACC, UVM, KICH and LGG, but favorable associations in SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for HYOU1 RNA expression.
This table summarizes HYOU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HYOU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HYOU1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, LUAD and COAD. The HNSC box plot shows higher HYOU1 RNA expression in tumor versus normal tissue (log2 FC = +1.136, t-test p < 0.001).
This table shows molecular features associated with HYOU1 in patient tissues and cancer cell lines. In patient samples, HYOU1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HYOU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
